Thyrocare Q2 FY27 Results Call Set for October 29

Q2 FY27 results are scheduled for October 29

Thyrocare Technologies Limited has scheduled its Q2 FY2026-27 earnings call for Thursday, October 29, 2026, at 6:00 p.m. The call is intended to discuss the company’s financial performance for the quarter and half year ended September 30, 2026. The company disclosed the investor-meet intimation under Regulation 30 of the Listing Obligations and Disclosure Requirements regulations. The scheduled event places Thyrocare’s September-quarter update on the same day as its board meeting. Investors will receive the company’s commentary after the board considers the unaudited financial statements. The announcement does not include the Q2 financial results or any guidance for the period.

Board to consider standalone and consolidated accounts

Thyrocare informed BSE that its board of directors is scheduled to meet on October 29, 2026. The agenda includes considering and approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Standalone results reflect the company’s own operations, while consolidated results include its subsidiaries and group entities. The board’s decision and the financial disclosures will form the basis of the subsequent earnings discussion. The company has not disclosed the meeting’s outcome ahead of the scheduled date.

Earnings call follows the board meeting process

The Q2 earnings call is scheduled for 6:00 p.m. on October 29. Such calls allow management to discuss reported performance and address questions from analysts and investors after the results announcement. Thyrocare’s intimation specifically identifies the discussion as covering both the quarter and the first half of FY2026-27. The company’s last earnings date was July 23, 2026, when it reported Q1 FY2026-27 performance. The next disclosure will therefore provide a view of how the business performed during July to September and across the first six months of the financial year.

Q1 FY27 revenue showed year-on-year growth

In Q1 FY2026-27, Thyrocare reported consolidated revenue of ₹240 crore, up 24.3% year on year and 7.18% sequentially. Standalone revenue was ₹225.6 crore, representing 26.1% growth from the corresponding quarter of the prior year. Management attributed the consolidated growth primarily to the core pathology business. The company said growth was supported by its franchisee and partnership business. These reported Q1 figures provide the immediate base for assessing the upcoming September-quarter results. However, Q1 growth figures do not indicate the eventual Q2 outcome, which has not yet been announced.

Profitability data from the preceding quarter

Thyrocare reported gross margin of 74.1% for Q1 FY2026-27, an improvement of more than 290 basis points year on year. Profit after tax for the quarter stood at ₹51.3 crore, with a profit after tax margin of 21.4%. Earnings per share was reported at ₹3.23, compared with ₹2.45 in Q1 FY2025-26. The figures indicate that the company entered the second quarter after a period of higher revenue and profit compared with the previous year. The Q2 disclosures will show whether these reported operating and profitability metrics changed during the September quarter.

Lab network expansion remains a business update

During the Q1 FY2026-27 earnings call, Thyrocare said its lab network stood at 43 labs in India and one lab in Tanzania. The company stated that it opened three labs during the quarter in Muzaffarpur, Bihar; Kurnool, Andhra Pradesh; and Prayagraj, Uttar Pradesh. The additions expanded its geographic footprint across India. The available announcement does not provide an updated lab-network count for Q2. Any further information on network additions, operating activity or regional expansion would need to come through the company’s results release or earnings-call discussion.

Key disclosed figures ahead of Q2 results

What the scheduled disclosure means for investors

The October 29 event is relevant because it will provide Thyrocare’s first official update for the September 2026 quarter. Investors can compare the new consolidated and standalone revenue figures with the ₹240 crore and ₹225.6 crore reported in Q1. Reported margins and profit after tax will also be important given the 74.1% gross margin and ₹51.3 crore profit after tax recorded in the preceding quarter. The half-year results will add the Q1 and Q2 performance periods together. Until the board approves the financial statements, no Q2 revenue, profit or earnings-per-share numbers have been disclosed in the available information.

Next steps on October 29

Thyrocare’s board is set to consider the unaudited standalone and consolidated results on October 29, 2026. The company will then hold its Q2 FY2026-27 earnings call at 6:00 p.m. the same day. The results release and investor discussion are expected to provide the confirmed financial data for the quarter and half year ended September 30, 2026. Investors will be able to assess the company’s reported revenue, margins, profitability and operational updates once those disclosures are made. For now, the scheduled board meeting and earnings call are the confirmed next events for Thyrocare Technologies.